These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 22065872)

  • 1. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
    Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
    Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
    Zander T; Scheffler M; Nogova L; Kobe C; Engel-Riedel W; Hellmich M; Papachristou I; Toepelt K; Draube A; Heukamp L; Buettner R; Ko YD; Ullrich RT; Smit E; Boellaard R; Lammertsma AA; Hallek M; Jacobs AH; Schlesinger A; Schulte K; Querings S; Stoelben E; Neumaier B; Thomas RK; Dietlein M; Wolf J
    J Clin Oncol; 2011 May; 29(13):1701-8. PubMed ID: 21422426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
    Scheffler M; Zander T; Nogova L; Kobe C; Kahraman D; Dietlein M; Papachristou I; Heukamp L; Büttner R; Boellaard R; Lammertsma AA; Querings S; Stoelben E; Engel-Riedel W; Neumaier B; Wolf J
    PLoS One; 2013; 8(1):e53081. PubMed ID: 23308140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
    J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
    Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
    Suleiman AA; Frechen S; Scheffler M; Zander T; Kahraman D; Kobe C; Wolf J; Nogova L; Fuhr U
    J Thorac Oncol; 2015 Jan; 10(1):84-92. PubMed ID: 25226426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
    Bengtsson T; Hicks RJ; Peterson A; Port RE
    J Nucl Med; 2012 Apr; 53(4):530-7. PubMed ID: 22414632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.